LiverLearning®: 2021 Webinar: Microbiome in NASH and Cirrhosis

In this one-hour webinar, learn about the pathophysiology of microbiome and liver disease, microbiome in NASH and microbiome in cirrhosis and other liver conditions.Suzanne Devkota Suzanne Devkota, PhD is Director of Microbiome Research at Cedars-Sinai Medical Center in Los Angeles and Assistant Professor of Medicine at UCLA, as well as an adjunct investigator at the Joslin Diabetes Center at Harvard Medical School.

Reply

Patricia Ruiz, Andres Valdivieso, Ibone Palomares, Mikel Prieto, Alberto Ventoso, Patricia Salvador, Maria Senosiain, Jose Ramon Fernandez, Milagros Testillano, Francisco Javier Bustamante, Mikel Gastaca – 10 October 2021

Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease

Suet‐Ying Kwan, Jingjing Jiao, Aron Joon, Peng Wei, Lauren E. Petty, Jennifer E. Below, Carrie R. Daniel, Xiaogang Wu, Jianhua Zhang, Robert R. Jenq, P. Andrew Futreal, Ernest T. Hawk, Joseph B. McCormick, Susan P. Fisher‐Hoch, Laura Beretta – 10 October 2021

Aberrant hepatic trafficking of gut‐derived T cells is not specific to primary sclerosing cholangitis

Jonathon J. Graham, Sujit Mukherjee, Muhammad Yuksel, Rebeca Sanabria Mateos, Tengfei Si, Zhenlin Huang, Xiahong Huang, Hadil Abu Arqoub, Vishal Patel, Mark McPhail, Yoh Zen, Nigel Heaton, Maria Serena Longhi, Michael A. Heneghan, Rodrigo Liberal, Diego Vergani, Giorgina Mieli‐Vergani, Yun Ma, Bu’Hussain Hayee – 10 October 2021

Shelter‐Based Integrated Model Is Effective in Scaling Up Hepatitis C Testing and Treatment in Persons Experiencing Homelessness

Mandana Khalili, Jesse Powell, Helen H. Park, Dylan Bush, Jessica Naugle, Margaret Ricco, Catherine Magee, Grace Braimoh, Barry Zevin, J. Konadu Fokuo, Carmen L. Masson – 9 October 2021 – Hepatitis C virus (HCV) prevalence is high among people experiencing homelessness, but barriers to scaling up HCV testing and treatment persist. We aimed to implement onsite HCV testing and education and evaluate the effectiveness of low‐barrier linkage to HCV therapy among individuals accessing homeless shelters.

Subscribe to